Fig 1: Gemin4 regulates COPI subunit expression, proliferation and Golgi morphology.A LNCaP cells were treated with shRNA targeting GEMIN4 for 48 h. Protein expression levels were assessed by western blotting. Actin was used as loading control. B LNCaP cells were transiently transfected with a Gemin4 expression construct and protein expression levels were assessed by western blotting. Actin was used as a loading control. C Cell proliferation in Gemin4 knockdown and overexpressing LNCaP cells was compared to the respective control: control shRNA and EGFP. Cells were grown for 48 h in media supplemented with 10% charcoal-stripped serum. Mean ± SD, N = 3 independent experiments with 3 technical repeats; **P = 0.0064, ns = 0.72. D Quantification of Golgi area (TGN46-postive) from confocal images (shown in E, F) in Gemin4 knockdown and overexpressing LNCaP cells. Mean ± SD. Twenty-two knockdown cells and 20 overexpressing cells were analysed per group. **P = 0.0030, ns = 0.24. E, F Images showing maximum intensity z-projections of confocal images of LNCaP cells transiently expressing EGFP-tagged shRNA or a Gemin4 expression constructs. Cell were stained with a TGN46 antibody (magenta). Scale bar, 25 µm. G Bar graph showing proliferation of LNCaP cells treated with 25 µM STO-609 for 120 h normalised to the DMSO control. Three independent experiments with three technical repeats were analysed. Mean ± SD; ***P = 0.0002. H LNCaP cells were treated with 25 µM STO-609 for 120 h. Protein expression of COPI components and Gemins were assessed by western blotting of 25 µg cell extracts separated on a SDS-PAGE gel. Actin was used as a loading control. Densitometry was performed on two experiments and normalised to control. Mean ± SD. I Bar graph showing the impact of 25 µM STO-609 treatment for 120 h in LNCaP cells on Golgi area (TGN46-positive) compared to CaMKK2 knockdown (shRNA2) cells. Mean ± SD. N = 31 cells; ****P < 0.0001.
Fig 2: Identification of the COPI coat complex as a novel interaction partner of the CaMKK2-Gemin4 protein complex.A A schematic outlining the Gemin4 peptide pulldown experiment using biotinylated CaMKK2-binding motif (CBM) as bait from cell lysates of LNCaP cells treated with androgen (R1881) or an ethanol control. Bound proteins were identified by western blotting or mass spectrometry. B The streptavidin pulldown of biotinylated Gemin4 CBM and control peptide was analysed by western blotting to demonstrate enrichment of known interactors CaMKK2 and Gemin proteins. C Proteins that bound specifically to the Gemin4 CBM peptide were identified with mass spectrometry and the data set was assessed by pathway analysis (GO cellular location). The top ranked pathways are shown in a table. D A Gemin4 CBM peptide pulldown was used to validate the novel interactions of Gemin4 identified by the pathway analysis. Proteins bound by the peptide from LNCaP cell extract was analysed by western blot using antibodies for CaMKK2 and three components of the COPI complex; α-COP, δ-COP and ζ-COP.
Fig 3: Identification of novel CaMKK2 interaction partners.A Schematic outlining the proteomics experimental design and workflow to identify CaMKK2-interacting proteins by co-immunoprecipitation (co-IP). HEK293 cells were transfected with EGFP-tagged CaMKK2, co-immunoprecipitated proteins were identified by mass spectrometry and the data were compared with a previously published data set [6]. B Immunoprecipitation of endogenous CaMKK2 from LNCaP cells showed co-immunoprecipitation of the Gemin complex. Immunoprecipitates (IP) with a control IgG were compared with those of CaMKK2 IgG, input lysate and unbound supernatant (SN). Bound proteins were evaluated by western blotting with the indicated antibodies. C A peptide array of full-length Gemin4 divided into 20 amino acid peptides with a 17 amino acid overlap was spotted on two nitrocellulose membranes. The membranes were incubated with either GST-CaMKK2 or GST alone. Bound GST protein was detected with a HRP-conjugated GST antibody. Yellow circles indicate peptides that bound CaMKK2 and had overlapping sequence with neighbouring peptides and red circles denote peptides that bound CaMKK2 but did not contain sequence overlap. A schematic drawing illustrates the sequence location of the highlighted peptides, which were concentrated in the first 370 aa of the Gemin4 sequence. D A peptide array of the N-terminal region of Gemin4 (aa 1–370) using 20 aa peptides with a 19 aa overlap. The peptide array was incubated with GST-CaMKK2 and GST control. The yellow box highlights the region in Gemin4 where GST-CaMKK2 but not GST bound. E Multiple sequence alignment of the CaMKK2-binding motif (CBM; aa 351–359) in Gemin4 identified in the peptide array illustrates sequence conservation across species. F To verify the specificity of the interaction in solution recombinant GST-tagged Gemin4 (aa 1–370) was used in a pulldown assay with LNCaP cell extracts. Equal amounts of control GST and GST-Gemin4 were used in the assay. The CaMKK2 binding was detected by western blotting.
Supplier Page from OriGene Technologies for Gemin 4 (GEMIN4) Human shRNA Lentiviral Particle (Locus ID 50628)